15th January 2020
Nuformix plc
("Nuformix" or "the Group"),
Amendement to Notice
On 10 January 2020, the Group announced the receipt of Notice of Exercise 1,250,000 ordinary shares of 0.1p each in the Company (the "Warrant Shares") and that dealings in the Warrant Shares were expected to commence on 14 January 2020.
This date has now been amended such that dealings in the Warrant Shares are expected to commence on 16 January 2020.
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain. 15
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer Email: [email protected] |
+44 (0)1223 627222 |
Novum Securities Limited Jon Belliss / Colin Rowbury |
+44 (0)20 7399 9427 |
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
